CellaVision AB (publ) (STO:CEVI) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Shareholders might have noticed that CellaVision AB (publ) (STO:CEVI) filed its third-quarter result this time last week. The early response was not positive, with shares down 8.2% to kr165 in the past week. It was a credible result overall, with revenues of kr176m and statutory earnings per share of kr1.31 both in line with analyst estimates, showing that CellaVision is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the consensus forecast from CellaVision's five analysts is for revenues of kr840.2m in 2026. This reflects a solid 12% improvement in revenue compared to the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr859.9m and earnings per share (EPS) of kr8.06 in 2026. So we can see that while the consensus made a small dip in revenue estimates, it no longer provides an earnings per share estimate. This suggests that the market is now more focused on revenue after the latest result.

Check out our latest analysis for CellaVision

We'd also point out that thatthe analysts have made no major changes to their price target of kr223. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic CellaVision analyst has a price target of kr240 per share, while the most pessimistic values it at kr200. This is a very narrow spread of estimates, implying either that CellaVision is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 9.7% growth on an annualised basis. That is in line with its 9.5% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 15% annually. So it's pretty clear that CellaVision is expected to grow slower than similar companies in the same industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their revenue estimates for next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates it is expected to perform worse than the wider industry. The consensus price target held steady at kr223, with the latest estimates not enough to have an impact on their price targets.

At least one of CellaVision's five analysts has provided estimates out to 2027, which can be seen for free on our platform here.

We also provide an overview of the CellaVision Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.